FDA Warns Eye Care Company Conducting Unapproved Clinical Trial Of Drug-Device Product
Executive Summary
The FDA sent a warning letter to Arbor Center for EyeCare for failing to submit an IND before beginning a trial of a novel drug-device combination product.
You may also be interested in...
Ophthalmic Dispensers Recommended Class I Designation By FDA Panel
The FDA’s Ophthalmic Devices Panel approved a Class I designation for ophthalmic dispensers, which were reclassified from drugs to devices after the Genus v. FDA decision.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
Creating Standards For Responsible AI In Health Care
Medtech Insight spoke to Brian Anderson about creating standards for responsible AI and the policy developments he’s looking forward to in 2024.